Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB00661_DB01263> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB00661_DB01263 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00661_DB01263 label "DDI between Verapamil and Posaconazole - Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed. [drugbank_resource:DB00661_DB01263]" assertion.
- drugbank_resource:DB00661_DB01263 identifier "drugbank_resource:DB00661_DB01263" assertion.
- drugbank_resource:DB00661_DB01263 title "DDI between Verapamil and Posaconazole - Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed." assertion.